2020-11-11T11:44:59-00:00 2019-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2019-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 98101 Michael Labosier Chief Financial Officer 2020-11-11 true Sue Robison 2069134000 2020-11-11 204.147.223.1 2020-11-11 19:42:56 PS P 2D777907B0975C575C8D1E5F6EEE6AF7977F0150 D8897A10968BD4A76AAFC1D10C660AAB2141E34A 2019 2021-01-29 14:40:06Z Jane Buckner MD 1201 Ninth Avenue Seattle WA 981012795 73469519 false X benaroyaresearch.org X 1956 WA To advance the science that will predict, prevent, reverse, and cure diseases of the immune system. 21 16 336 7 0 59023034 62867601 8229643 9656398 191489 322628 347680 432312 67791846 73278939 22634522 23652782 0 26095485 29080641 0 0 18050564 18713253 66780571 71446676 1011275 1832263 84112856 95747100 39800841 45073162 44312015 50673938 X Advancing the science that will predict, prevent, reverse, and cure diseases of the immune system such as autoimmune disease, allergy, and asthma. false false 27576900 21982621 Immune Tolerance Network Program. See Schedule O. 8899817 1279738 Fundamental Immunology Programs - Includes Fundamental Immunology. See Schedule O. 9436609 158099 Translational, Clinical, and Systems Programs - Includes Translational, Systems, Interventional, and CRP. See Schedule O. 13057014 232324 9656398 58970340 true true false true false false false false false true true true false false true false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 82 0 true 336 true false false false false false false false false false false false false X 21 16 false false false false true true true true true false false true true true true true true true true false WA X Michael Labosier CFO 2063426505 1201 Ninth Avenue Seattle WA 98101 Gary Kaplan MD Director 001.00 054.00 X 0 1661792 331024 David Aboulafia MD Director 001.00 050.00 X 0 635488 59144 Joyce Lammert MD PhD Director 001.00 050.00 X 0 534963 104561 Jane Buckner MD Ex Officio, President 040.00 X X 492418 0 26200 William Kowk PhD Research Member 040.00 X 244059 0 28600 Carla Greenbaum MD Director 040.00 X 238252 0 31562 Steven Ziegler PhD Director of Academic Affairs 040.00 X 234294 0 22978 Margaret McCormick PhD Executive Director Chief Operating Officer 040.00 X 218634 0 30800 Michael Labosier Chief Financial Officer 040.00 X 191450 0 25562 Bolong Cao Business Development Director, Business Development 040.00 X 186128 0 29474 Lynn Rose Director of Scientific Administration 040.00 X 190130 0 22010 Daniel Campbell PhD Center Director of Discovery Science 040.00 X 186514 0 17729 Gerald Nepom MD PhD Program Director, ITN 024.00 X 158330 0 27444 Homer Lane Executive Director Chief Financial Officer 040.00 X 168551 0 6985 Catherine Zimmerman Director 001.00 X 0 0 0 Jeffrey S Wortley Director, Treasurer 001.00 X X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 David Williams Director 001.00 X 0 0 0 Diane St John Director, Secretary 001.00 X X 0 0 0 Proctor Shenk Director 001.00 X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Paul Hughes Director 001.00 X 0 0 0 Michael Gallatin Director 001.00 X 0 0 0 Frank Dvorak PhD Director, Vice-Chair 001.00 X X 0 0 0 Carla DewBerry Director, Chair 001.00 X X 0 0 0 Tom Cohen Director 001.00 X 0 0 0 Rebecca Campbell Director 001.00 X 0 0 0 Ben Reiber Director 001.00 X 0 0 0 Kirk Nelson Director 001.00 X 0 0 0 Robert Williams Director 001.00 002.00 X 0 0 0 2508760 2832243 764073 53 false true false DNA Brand Mechanics 1301 Fifth Avenue Suite 2600 Seattle WA 98101 Professional Services 146247 KPMG LLP 1918 Eighth Avenue Suite 2900 Seattle WA 98101 Auditing Consulting 115616 Riverbend Design Group LLC 414 Stewart St suite 215 Seattle WA 98101 Web Development Digital Communications 110310 Finley & Cook 601 N Broadway Shawnee OK 74802 Software Support 106353 4 3000000 48266738 11600863 62867601 Commercial Studies 621500 4280875 4280875 Collaborative Research Core Services 621500 5375523 5375523 9656398 322628 322628 622892 190580 432312 432312 432312 73278939 9656398 754940 21460813 21460813 0 2191969 2191969 0 1443449 663622 779827 0 20938237 15192282 5745955 1769420 1231506 537914 3230520 2248421 982099 1699015 1182504 516511 0 9413 9413 115616 115616 0 0 2343708 1641280 702428 177242 745 176497 122182 23165 99017 1403630 653435 750195 0 3401852 2805144 596708 347489 268212 79277 0 114501 84941 29560 758201 659635 98566 0 3254492 2602540 651952 57358 57358 Supplies and Miscellaneous Expenses 4446355 4322029 124326 Other Purchased Services 380574 243263 137311 Patient Costs 976976 976976 Research Participants Expenses 341518 341448 70 462146 176410 285736 71446676 58970340 12476336 0 5711406 5968573 576745 1346562 11995906 13407687 1591784 2190375 509432 642728 75226693 51536267 24914121 23690426 12066383 12334516 25745020 33053950 1002059 3112283 84112856 95747100 9535580 10369555 4548771 6925668 25716490 25037716 2740223 39800841 45073162 X 17232381 17545065 27079634 33128873 44312015 50673938 84112856 95747100 1832263 4529660 X false true X true true true X Virginia Mason Medical Center Seattle WA 59709893 71346495 60243416 59023034 62867601 313190439 59709893 71346495 60243416 59023034 62867601 313190439 30081850 283108589 430555 933027 994910 729749 945520 4033761 7021290 8553010 6781431 8229643 9656398 40241772 357465972 40241772 0.79200 0.79680 X 0.00000 0.00000 Part II Section B Line 10 2019 Other Income of 9,656,398 is comprised of 4,280,875 of Clinical Research Program revenue, 4,453,944 of Collaborative Research Agreement projects, 886,743 of External Core Income, and 34,836 of miscellaneous income. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 183519 123581 307100 71446676 1766048047 71446676 1766355147 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 275782 284247 294038 307100 1161167 250000 250000 250000 250000 1000000 1500000 163134 175480 180464 183519 702597 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0.Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 134,909 Direct Lobbying Expenditures 63,581. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2019. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. II-A A continued Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. 48,610 Grassroots Lobbying Expenditures 60,000 Direct Lobbying Expenditures. Excess Lobbying Expenditures 0. false false true true 756906 756906 49852993 30754795 19098198 215595 199672 15923 23141650 20581800 2559850 1259549 1259549 23690426 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 33053950 F 33053950 Federal income taxes Lease liability Relates to Right-of-Use Asset 2740223 2740223 77808599 4529660 4529660 73278939 73278939 71446676 71446676 71446676 X 1, Row 2 In accordance with ASC topic 842 Leases, the Research Institute adopted the new standard and recorded lease liabilities over lease terms between 3 and 10 years. The leases are primarily for real estate, including off-campus outpatient facilities, medical office buildings, and corporate and administrative offices. true Europe Including Iceland and Greenland Conferences Medical Research 29451 East Asia and the Pacific Conferences Medical Research 4213 North America Conferences Medical Research 1283 Europe Including Iceland and Greenland Grant Medical Research 1789606 East Asia and the Pacific Grant Medical Research 394025 North America Grant Medical Research 8337 2226915 2226915 Europe Including Iceland and Greenland Medical Research 811655 Wire Transfer Europe Including Iceland and Greenland Medical Research 596423 Wire Transfer Europe Including Iceland and Greenland Medical Research 231032 Wire Transfer Europe Including Iceland and Greenland Medical Research 134225 Wire Transfer Europe Including Iceland and Greenland Medical Research 16271 Wire Transfer East Asia and the Pacific Medical Research 277258 Wire Transfer East Asia and the Pacific Medical Research 96526 Wire Transfer East Asia and the Pacific Medical Research 12494 Wire Transfer East Asia and the Pacific Medical Research 7747 Wire Transfer North America Medical Research 8337 Wire Transfer 10 false false false false false false Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann&Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 11685 Medical Research Arkansas Children's Hospital Research Institute One Childrens Way Little Rock AR 722023591 710694931 501c3 46507 Medical Research Asthma Inc 9725 3rd Ave NE Seattle WA 98115 237219813 501c3 18988 Medical Research Children's Hosp of Philadelphia PO Box 8550 Phliladelphia PA 191781457 231352166 501c3 67524 Medical Research Children's Mercy Hospital 2401 Gillham Road Kansas City MO 64101 440605373 501c3 41893 Medical Research The Cleveland Clinic Foundation 9500 Euclid Avenue JJN5-001 Cleveland OH 44195 340714585 501c3 97334 Medical Research Columbia University Trustees of PO Box 29789 New York NY 100879789 135598093 501c3 80903 Medical Research Dana-Farber Cancer Institute Inc Attn Research Accounting Boston MA 02215 042263040 501c3 115073 Medical Research Denver Nephrologists PC 130 Rampart Way Suite 300B Denver CO 80230 840591433 13538 Medical Research Duke University PO Box 602651 Charlotte NC 282602651 560532129 501c3 1287080 Medical Research Emory University PO Box 935084 Atlanta GA 311935084 580566256 501c3 201493 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 167098 Medical Research Fred Hutchinson Cancer Research Center Mailstop J6-330 Seattle WA 98109 237156071 501c3 257933 Medical Research Hospital for Special Surgery 535 East 70th Str New York NY 10021 131624135 501c3 12868 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500 New York NY 100296574 136171197 501c3 1406824 Medical Research Indiana University Dept 78867 Detroit MI 482780867 356001673 501c3 137454 Medical Research Johns Hopkins University Central Lockbox c/o B of A Chicago IL 60693 520595110 501c3 468431 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280 Los Angeles CA 90025 462346264 501c3 45319 Medical Research Joslin Diabetes Center ATTN Fiscal Services Boston MA 022155306 042203836 501c3 62425 Medical Research Massachusetts General Hospital 55 Fruit Street Boston MA 02114 042697983 501c3 5841834 Medical Research Medical University of South Carolina 19 Hagood Avenue Ste 604 Charleston SC 29425 576000722 501c3 15919 Medical Research MITBroad Institute 415 Main Street Cambridge MA 02142 263428781 501c3 8388 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 18521 Medical Research New York University-School of Medicine 1 Park Ave Fl 11 New York NY 10016 135562308 501c3 19272 Medical Research Northwestern University 633 Clark Room G547 Evanston IL 60208 362167817 501c3 91798 Medical Research Ohio State University Office of Sponsored Programs Columbus OH 43210 316025986 501c3 12616 Medical Research Polyclinic Madison Center 904 7th Ave Seattle WA 98104 910369070 501c3 39093 Medical Research Rockefeller University 1230 York Ave New York NY 100656307 131624158 501c3 35835 Medical Research Rutgers the State University of New Jersey Office of Research and Sponsored Pr New Brunswick NJ 089018559 226001086 501c3 126221 Medical Research Sanford Research 2301 E 60th St N Sioux Falls SD 57104 460450378 501c3 81778 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 528866 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 283911 Medical Research State University of Iowa 118 S Clinton St - SCST Iowa City IA 52242 426004813 501c3 71518 Medical Research St Jude Children's Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 290310 Medical Research University Of South Florida PO Box 864568 Orlando FL 32886 593102112 Florida 7679 Medical Research University of WA Grants 12455 Collections Drive Chicago IL 606930001 916001537 Washington 1085117 Medical Research Univ of Minnesota Regents NW 5957 Minneapolis MN 554855957 416007513 Minnesota 84319 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 185610 Medical Research University of Pennsylvania PO Box 785541 Phliladelphia PA 171785541 231352685 501c3 172206 Medical Research University of Florida PO Box 113001 Gainesville FL 32611 596002052 501c3 13110 Medical Research University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas TX 75390 756002868 Texas 103452 Medical Research University of Michigan Box 223131 Pittsburgh PA 152512131 386006309 501c3 75904 Medical Research University of North Carolina at Chapel Hill PO Box 402420 Atlanta GA 303842420 566001393 501c3 91447 Medical Research University of Massachusetts Worcester 55 Lake Avenue North Worcester MA 016550002 043167352 501c3 11810 Medical Research University of Wisconsin Madison Board of Regents 600 Highland Ave Madison WI 53792 396006492 Wisconsin 40695 Medical Research University of Chicago 5841 S Maryland Ave Chicago IL 60637 362177139 501c3 11025 Medical Research University of California San Francisco Controllers Office San Francisco CA 941430897 946036493 501c3 6546206 Medical Research University of Pittsburgh Research/Cost Accounting Pittsburgh PA 152517220 250965591 501c3 522144 Medical Research University of Alabama at Birmingham 1720 2nd Ave South Birmingham AL 35294 636005396 501c3 9860 Medical Research University of Miami 1320 S Dixie Highway Coral Gables FL 331462926 590624458 501c3 6618 Medical Research University of California Los Angeles 11000 Kinross Ave Ste 211 Los Angeles CA 90095 956006143 501c3 36807 Medical Research University Of Texas Health Science Center Houston 7000 Fannin St Houston TX 770305400 741761309 Texas 30300 Medical Research Vanderbilt University Department of Finance Dallas TX 753121236 620476822 501c3 140098 Medical Research Vital Prospects Clinical Research Institute PC 7307 S Yale Ave Suite 200 Tulsa OK 74136 261814411 501c3 13903 Medical Research Washington University in St Louis 700 Rosedale Avenue Campus Box 1034 St Louis MO 63012 460653611 Missouri 10601 Medical Research Weill Medical College of Cornell University Attn Research Accounting New York NY 100226102 131623978 New York 220750 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 28249 Medical Research 56 1 Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X X true true false false false false false false false false false Michael Labosier Chief Financial Officer 191450 19000 6562 217012 Lynn Rose Director of Scientific Administration 188630 1500 19038 2972 212140 Margaret McCormick PhD Executive Director Chief Operating Officer 218634 25000 5800 249434 Steven Ziegler PhD Director of Academic Affairs 234294 17866 5112 257272 William Kowk PhD Research Member 244059 25000 3600 272659 Gerald Nepom MD PhD Program Director, ITN 158330 24000 3444 185774 Gary Kaplan MD Director 1204109 193393 264290 287869 43155 1992816 David Aboulafia MD Director 634300 1188 27343 31801 694632 Joyce Lammert MD PhD Director 389432 52269 93262 89844 14717 639524 Carla Greenbaum MD Director 238252 25000 6562 269814 Jane Buckner MD Ex Officio, President 391383 101035 25000 1200 518618 Homer Lane Executive Director Chief Financial Officer 88163 80388 6125 860 175536 Daniel Campbell PhD Center Director of Discovery Science 186514 12425 5304 204243 Bolong Cao Business Development Director, Business Development 186128 25000 4474 215602 Part I Line 1a Social club dues are provided to two members of the senior leadership team who use the club memberships for business purposes. These payments are treated as non-taxable. Part I Line 3 Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. A WA Econ Devel Fin Auth-2019 Series A 911493002 000000000 2019-02-26 25716490 See Part VI false true false B WA Econ Devel Fin Auth-2019 Series B 911493002 000000000 2019-02-26 6000000 See Part VI false true false A 569384 25716490 25716490 true false true true B 6000000 263427 5736573 true false true true A false false false true true 0.03030 0.03030 false false true B false false false true true 0.03030 0.03030 false false true A false true true false false false true B false true true false false false true A true B true Part I Line A Column F Purposes To currently refund WEDFA Series 2012 B bonds issued 06/01/2012, and WEDFA Series 2016 bonds issued on 06/01/2016. Part I Line B Column F Purposes To fund research facility improvements and equipment purchases on a draw-down basis over a three-year period ending in 2022. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is one of the few research institutes in the world devoted to finding causes and cures for autoimmune disease and other diseases of the immune system including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, inflammatory bowel disease, allergy and cancer. We believe a breakthrough against one of these diseases can lead to progress against them all. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight, development support through the Virginia Mason Foundation as well as being a partner in clinical and translational research. In 2019, BRI launched an ambitious strategic plan with a bold mission to predict, prevent, reverse and cure diseases of the immune system to achieve our vision of a healthy immune system for everyone. Discoveries at BRI are accelerated by our talented researchers, collaborative culture and application of new technologies and data analytics. However, in order to fully realize our mission, we need to better understand what causes the immune system to fall out of balance and what we can do to restore it to health. To that end, BRI has now organized its scientific activities into four new Centers of Discovery 1 Fundamental Immunology, directed by Daniel Campbell, PhD 2 Translational Immunology, directed by Karen Cerosaletti, PhD 3 Interventional Immunology, directed by Carla Greenbaum, MD and 4 Systems Immunology, directed by Peter Linsley, PhD. The Centers work together by building on the discoveries of each, with scientists applying tools and insights across the spectrum of immune system diseases to accelerate research advances. BRI is led by President Jane H. Buckner, MD, and Executive Director/COO Margaret McCormick, PhD. In 2019, through a new funding opportunity BRI initiated a novel Gut Immunology program, which works across the Centers to unite scientists who study different aspects of the same diseases. Many of BRIs research faculty serve concurrently as affiliate professors at the University of Washington and mentor postdoctoral fellows, graduate students and summer interns. Form 990, Part III, Line 4 One unique quality of BRI is the close integration of four types of medical research - laboratory research, translational research, clinical research and systems biology - to improve lives. Our scientists collaborate to explore basic science as well as clinical applications, which is the best way to design studies with the highest potential for success. At BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. Selected 2019 advancements of the Immune Tolerance Network and in BRIs Centers of Discovery are highlighted as follows. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in these clinical areas Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2019 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2019 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 194 sub-awards in 2019 in support of 27 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted two supplemental funding requests in 2019. These requests were awarded, bringing in an additional 3.17M in funding to the ITN BRI. b Partnerships The ITN continued its relationship with two pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on both of these trials. 4 Publication Activity In 2019, 26 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. 5 Grant Renewal Application With the current ITN grant funding ending in February 2021, the preparation of the grant renewal application was a major focus in Q4, 2019. The renewal was successfully submitted, with expected award notification in late 2020. Form 990, Part III, Line 4b Center of Fundamental Immunology advances include 1 Linking a New Type of Cell with a Deadly Inflammatory Disorder - A research team made a discovery that lights the way to treat life-threatening complications of autoimmune and viral diseases. The discovery, published in the journal Science, could lead to new treatments for a deadly form of inflammation in children with systemic juvenile idiopathic arthritis SJIA, malaria and Kawasaki disease as well as patients with lupus. The research team found a unique type of cell, which they termed inflammatory hemophagocytes iHPCs, that eat red blood cells in MAS and malaria. They demonstrated that iHPCs develop under the influence of two specific proteins that recognize infection and are associated with autoimmune disease. Next steps will involve collaborations with pediatricians and pediatric rheumatologists to look for iHPCs in the blood of children with autoimmune disease related anemia, as well as healthy individuals, with a goal of quickly identifying potential targets for treatments. Comparisons with blood samples infected by malaria are already under way. 2 A Skin Immune Cell Discovery Challenges Assumptions about T cells - BRI scientists scrutinized a newly identified population of human immune cells in the blood that appear to have everything in common with infection-fighting T cells isolated from the skin. Scientists demonstrated that T cells that were previously assumed to stay in the skin, and are referred to as tissue-resident memory T cells, can exit skin tissue, enter the blood and circulate throughout the body. These T cells can then relocate into skin at other locations of the body. In addition to potential implications for treatment of wounds and skin infections, the identification of this cell population presents an opportunity to identify therapies for immune-related diseases that affect the skin, including scleroderma, psoriasis and a form of lymphoma called mycosis fungoides. Form 990, Part III, Line 4c Center for Translational Immunology is a research approach that allows scientific observations made in the basic research lab to be quickly evaluated in patient samples, refining our understanding of human disease in an expedient and systematic way. This research is translating new diagnostic and treatment approaches that may improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program crosses a spectrum of diseases caused by or aggravated by the immune system, including cancer and infectious disease. The BRI biorepositories, or biobank, is a collection of blood, serum and tissue samples, as well as medical histories, from healthy volunteers and individuals with diseases involving the immune system. Sample collections began in 2000. BRI scientists and physician collaborators work together to study the blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy, asthma and cancer. Advancements in 2019 included the following 1 Personalized Treatments for Peanut Allergy - BRI furthered a two-pronged study to accelerate discovery of treatments for peanut allergy through a collaboration involving three BRI labs, Virginia Mason physicians and sponsors of two clinical trials. The study first investigated peanut allergy patients immune responses and classified them into subgroups. In the second part of the study, researchers are evaluating treatment options used in a pair of clinical trials to determine how specific treatments can be matched to specific patients to teach their immune systems to tolerate peanut protein. 2 Sound Life Project - BRI launched the Sound Life Project, a two-year study in which researchers will track healthy immune systems over time. Seattle-area adults in two age cohorts - 25-35 and 55-65 - began to participate in this groundbreaking study to build a baseline of knowledge about the human immune system and the influence of environmental/lifestyle factors. BRI will use this information about healthy immune systems to serve as a foundation for existing and future disease research programs. The project is in the initial phase of a research partnership led by the Allen Institute for Immunology. 3 Autoimmune Disease Research in the Down Syndrome Population - With the help of a Virginia Mason pediatrician, BRI leveraged a grant from the National Institutes of Health to build a Down syndrome DS biorepository to research the connection between DS and autoimmune disease. The collection includes blood, serum and tissue samples, as well as medical histories, from volunteers, people with DS and their relatives, with and without autoimmune diseases. The DS population has long been underrepresented in medical research, and nearly 50 percent of this population is living with at least one autoimmune disease. BRI is among the first to be awarded a grant dedicated to autoimmune disease in the DS population. 4Identifying biomarkers that predict the success of checkpoint inhibitor immunotherapy drugs used to treat certain types of cancer - Despite the success of checkpoint inhibitors at improving cancer survival rates, they do not work in all patients and often have serious side effects including sudden-autoimmune-like symptoms called immune related adverse events irAEs. BRI scientists took a much closer look at how immune response cells -- known as T cells -- are affected by checkpoint inhibitor drugs. Ultimately, the scientists hope to identify T cell biomarkers that predict which patients are at the lowest or highest risk for autoimmune effects after receiving checkpoint inhibitors. They also explored ways to improve the ability of checkpoint inhibitors to kill cancer cells while protecting healthy tissue. The BRI Clinical Research Program works closely with oncologists at Virginia Mason to enroll subjects in this study. In a second project involving immunotherapy, BRI scientists collaborated to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer. After treatment with checkpoint inhibitors, roughly 1 of cancer patients develop a kind of insulin-dependent diabetes that appears similar to type 1 diabetes. The goal of this collaborative research initiative was to better understand this phenomenon and to identify the causes of diabetes in these patients. The autoimmunity research collaborators also intended to shed light on the causes of T1D in the broader population. Form 990, Part III, Line 4c continued 5 Pursuing a Revolution in IBD Treatment - BRI researchers searched for biomarkers that could help make IBD treatment more precise and effective through a precision medicine approach that could tailor treatment to individual patients. They worked to identify biomarkers - proteins and other molecules in patients blood or cells - to predict response to a specific drug. The researchers started this study by taking blood samples from Virginia Mason IBD patients before they started using the drug vedolizumab, and then again after they had taken several doses, carefully analyzing the immune cells in these samples. Vedolizumab binds to a specific type of receptor on the outside of some immune cells, and the researchers discovered that some people who have more of this receptor respond better to the drug. 6 Aiming for Better Lupus Treatments - Immune cells protect us by hunting down bacteria and viruses, but a BRI team found that cells that lack a gene called ATG5 never stop attacking. Eventually, they aim at healthy cells and cause lupus. Scientists think it might be possible to stop these attacks by using medications to reactivate ATG5 and other genes, which could switch off overactive immune cells. A second research team identified a different gene involved in lupus BANK1. This gene plays a role in immune cells called B cells. Many B cells make tiny proteins called antibodies, and some of those antibodies attack healthy cells, causing lupus. The team showed that BANK1 may increase the number of B cells that make antibodies, especially in people with lupus who have a particular BANK1 variant. The work is helping us move toward better, more personalized treatments of lupus. Form 990, Part III, Line 4c continued The Center for Interventional Immunology translates discoveries in the lab to patient therapies in the clinic through small and large-scale clinical studies. The Center for Interventional Immunology is also home to the Diabetes Clinical Research Program as well as the Clinical Research Program CRP, which provides compliance oversight of all interventional studies at BRI and Virginia Mason Medical Center. The CRP also manages all clinical research conducted by Virginia Mason Medical Center physicians and supports a number of specimen collection protocols developed within the Translational Immunology Center, particularly in cancer research. Details about CRP activities are provided below. Advancements in 2019 included the following 1 BRI leads the Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment, serving as the TrialNet hub of 28 clinical centers working with more than 200 screening and clinical research sites across the U.S. and six other countries. 2 An Immunotherapy Drug that can Delay T1D - A TrialNet prevention study involving diabetes researchers and volunteers at BRI showed a drug that targets the immune system - teplizumab - can delay type 1 diabetes a median of two years in children and adults at high risk. That is good news for relatives of people with type 1 diabetes, who are at 15 times greater risk of the disease than the general population. Samples collected during the trial are being studied to help researchers understand why certain people responded to the drug better than others, and next, researchers hope to conduct additional studies to look for ways to extend the benefits of the drug. 3 The TrialNet Pathway to Prevention study screened relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes have about a three to four percent chance of testing positive for autoantibodies associated with diabetes. At-risk relatives are offered additional tests to estimate their chances of developing type 1 diabetes. Those who qualify have the opportunity to enroll in a prevention trial. All research volunteers are closely monitored for early detection of type 1 diabetes. Early detection of type 1 diabetes may improve blood sugar control and reduce the chances of complications. 4 Home to the JDRF Core for Clinical Assay Validation CAV, BRI plays an important role in identifying type 1 diabetes biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key biomarkers, such as those indicating which patients will keep making insulin for years and which patients wont. The CAV also helps maintain quality control for a worldwide network of research labs by asking them to perform specific tests and reviewing their results. 5 The Center for systems Immunology analyzes large and complex data sets across all the other Centers, to identify patterns that accelerate discovery and disease breakthroughs. Advancements in 2019 included the following Identifying and helping T1D fast progressors - When some people are diagnosed with type 1 diabetes T1D, the disease progresses so quickly that their pancreas stops making insulin within a year. For others, the process is slower and their disease is easier to manage. BRI researchers revealed that it is possible to identify the fast progressors early and match them with treatments that help keep them healthy for longer. This research showed that slow progressors have higher levels of exhausted CD8 T cells - cells that are worn out from attacking the pancreas. The discovery could lead to a test that identifies how quickly individual patients will lose their ability to make insulin. Form 990, Part III, Line 4d Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center, which combines the expertise of BRI in management of interventional studies with the remarkable care of a quality healthcare leader. The BRI Clinical Research Program supports BRI and Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. Each year the Clinical Research Program staff enrolls approximately 1500 study participants into Virginia Mason trials. This program involves approximately 150 research investigators at Virginia Mason Medical Center, and oversees more than 400 active studies with more than 275 studies currently open to enrollment. Teaming Up Against Celiac Disease - Researchers used tetramer technology pioneered by a BRI scientist and used to isolate particular immune cells to pinpoint attacker T cells in blood samples from patients with celiac disease. In these patients, only about three in 100,000 T cells react to gluten, sparking immune attacks that lead to the diseases debilitating symptoms. The researchers are working to figure out why these cells attack the body, perhaps leading them to diagnostic tools and therapies for patients with celiac symptoms - as well as their family members, because autoimmune disease can run in families. Testing a New MS Therapy - a research study at BRI and Virginia Mason seeks to find out if an experimental oral drug, similar to a currently available MS medication, would be just as effective as the current one, but with fewer gastrointestinal side effects. In an earlier study, half the research participants took this experimental drug and half took the current drug. Participants who finished the five-week study then enrolled in a two-year study of the experimental drug, under way in 2019. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6,7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The VMHS Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provide the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final Form 990 is reviewed by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2019 were Jane Buckner, BRI President and Director, Carla Greenbaum, BRI Director, Margaret McCormick, Executive Director and Chief Operating Officer, and Michael Labosier, Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 N/A false Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 Education WA Sec 501c3 9 VMMC false Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 Health Care WA Sec 501c3 3 VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1200 Ninth Avenue Seattle WA 98101 910653422 0 0 0 71446676 71446676 40449 10112 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 134909 63581 198490 1174521397 1174719887 665053 166263 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 0 0 0 6260831 6260831 3544 886 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 14136817 14136817 8003 2001 0 0 0 Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 48610 60000 108610 499682326 499790936 282950 70738 0 0 0